Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CIPROFLOXACIN vs FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
None Documented
None Documented
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Primarily renal (80-90% unchanged); biliary/fecal <4%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic